Email Medtest Medtest Headquarters Medtest Facebook Medtest Linkedin

MedTest Holdings Announces a New Chief Financial Officer

Jun 15, 2016 - press releases

For Immediate Release: (Canton, Michigan)  Effective June 12, 2016, Davina Chow has been appointed as the new Chief Financial Officer (CFO) by MedTest Holdings replacing Tim Allen effective June 10, 2016. 

Davina brings 20 years of financial leadership experience with multinational publicly traded companies in the diagnostics industry. Prior to joining MedTest, Davina held the Controller position at Siemens Healthcare, as well as having held key leadership roles within its predecessors which include Dade Behring Canada, Behring Diagnostics Canada and Syva Canada. Most recently, Davina was part of the Business Optimization Team at Victorian Order of Nurses, where she optimized financial and SAP FICO processes. Davina holds a Bachelor of Commerce degree in Accounting and Finance from Concordia University in Montreal, Quebec and is a Certified Management Accountant, member of Chartered Professional Accountants of Canada.

Hanjoon Ryu, CEO of MedTest, stated: “Davina’s strong focus on our customers and her extensive experience in the in-vitro diagnostic industry enables her to lead MedTest through today’s challenging market and to strengthen our competitiveness for the future.  I want to express my sincere gratitude to Tim Allen for his numerous contributions and wish him the best of luck in his new adventure.”

About MedTest:  MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.  In June 2013, MedTest acquired Pointe Scientific, a US-based company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.  In October 2014, MedTest acquired Clinitox Diagnostix, a Canadian-based company, which provides drugs of abuse confirmatory testing capabilities via liquid chromatography/mass spectrophotometry (LC/MS) instrumentation and associated reagents and consumables as pre-packaged kits.  Implementation consulting provides the customer with on-site assistance in setting up their LC/MS testing and developing the standard operating procedures enabling the laboratory to initiate testing sooner and reduce costly start-up costs.

For additional information, please contact:

MedTest
Debbie Whitehair, MT(ASCP)SC
Vice President, Marketing
484-748-1603
dwhitehair@medtest.com
www.medtest.com

                                                              

PR-M3111-06   06/16